HIV Specific Humoral Immune Response in Rio de Janeiro, Brazil

Memorias do Instituto Oswaldo Cruz

Volumn 93, Issue 3, 1998, Pages 391-398

  Bongertz, V ^b   Costa, C I ^b   Guimaraes M L ^b   Soares da Costa, M F G ^b   Grinsztejn, B ^a   Bastos, F I ^b   Pilotto, J H ^c   Joao Filho E C ^d   Loureiro, R ^e   Chequer, P ^f   Telles, P R ^g   Galvao Castro B ^b   Morgado, M G ^b   Santos, V G V ^b   Rolla, V C ^b   Cavalcante, S ^b   Galhardo, M C G ^b   Guimaraes M R C ^b   Khalili, R ^b   Valles De Souza, R ^b  

^a Funda??o Oswaldo Cruz   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Hospital Geral de Nova Iguaçu   (Brazil)

^d HOSPITAL DOS SERVIDORES DO ESTADO   (Brazil)

^e Centro de Saude Munaldo   (Brazil)

^f Programa Nacional de DST/AIDS   (Brazil)

^g STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antibody specificity; Genotypes; HIV 1; Neutralization

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1;

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; BRAZIL; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE TRANSMISSION; FEMALE; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; PREGNANCY; SERODIAGNOSIS;

ANTIBODY FORMATION; ANTIBODY SPECIFICITY; BRAZIL; COHORT STUDIES; FEMALE; GENOTYPE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEUTRALIZATION TESTS; PREGNANCY;

EID: 0032065370     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02761998000300022     Document Type: Article

References (38)

1. Albert J, Abrahamson B, Nagy K, Aurelius E, Gaines H, Nystrom G, Fenyoe EM 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4: 107-112.
2. Albert J, Bjoerling E, Von Gegerfelt A, Scarlatti G, Thorstensson R, Zhang Y, Fenyoe EM 1993. Antigen detection is a reliable method for evaluating HIV/SIV neutralization assays. AIDS Res Hum Retroviruses 9: 501-504.
3. Arendrup M, Sönnerborg A, Svennerholm B, Akerblom L, Nielsen C, Clausen H, Olofsson S, Nielsen JO, Hansen JES 1993. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol 74: 855-863.
4. Bastos FI, Soares-da-Costa MFG, Telles PR, Morgado MG, Bongertz V 1997. Higher seroreactivity with env epitopes in HIV-1 infected IDUs. p.11. Segundo Simpósio Brasileiro de Pesquisa Basica em HIV/AIDS, Angra dos Reis, RJ.
5. Björling E, Scarlatti G, Von Gegerfelt A, Albert J, Biberfeld G, Chiodi F, Norrby E, Fenyö EM 1993. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 193: 528-530.
6. Bloom BR 1996. A perspective on AIDS vaccines. Science 272, 1888-1889.
7. Bongertz V, Costa CI, Santos VGV, The HEC/Fiocruz AIDS Clinical Research Group, João Filho EC, Galvão-Castro B, Morgado M 1997. Correlation between Susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies. AIDS 11: 977-986.
8. Bongertz V, Jansson M, Flodby P, Morgado MG, Galvão-Castro B, Wigzell H 1994. Analysis of antibody specificity against the third variable region of the envelope gp120 of HIV-1 in plasma from HIV-1 positive individuals resident in Brazil. Braz J Med Biol Res 27: 1225-1236.
9. Carrow EW, Vujcic LK, Glass WL, Seamon KB, Rastogi SC, Hendry RM, Boulos R, Nzila N, Quinnan Jr GV 1991. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1 MN in sera from Africa and the Americas. AIDS Res Hum Retroviruses 7: 831-838.
10. CDC - Centers for Disease Control 1986. Classification system for human T-lymphotropic virus type III/lymphoadenopathy associated virus infections. Ann Int Med 105: 234-237.
11. Cheingsong-Popov R, Callow D, Beddows S, Shaunak S, Wasi C, Kaleebu P, Gilks C, Petrascu IV, Garaev WM, Watts DM, Constantine NT, Weber JN 1992. Geographic diversity of HIV-1: serologic reactivity to env epitopes and relashionship to neutralization. J Inf Dis 165: 256-261.
12. Delwart EL, Shpaer EG, Louwagie J, Mc Cutchan FE, Grez M, Ruebsamen-Waigmann H, Mullins J 1993. Genetic relationships determined by a DNA heteroduplex motility assay: Analysis of HIV-1 env genes. Science 262: 1257-1261.
13. Des Jarlais DC, Castriel C, Friedman SR 1988. The new death among IV drug users, p. 256-281. In IB Corless, M Pittman-Lindeman (eds), AIDS: Principles, Practices and Politics, Hemisphere Publ Co, New York.
14. Fenyö EM, Albert J, McKeating J 1996. The role of the humoral immune response in HIV infection. AIDS 10 (Suppl A): S97-S106.
15. Gadelha AJ 1997. Casos notificados de AIDS no Municipio do Rio de Janeiro, 1983-1993. Análise de sobrevida, PhD Thesis, Universidade de São Paulo, SP, 152 pp.
16. Galvão-Castro B, Couto-Fernandez JC, Mello MA, Linhares de Carvalho MI, Castello Branco LR, Bongertz V, Ferreira PC, Morgado MG, Tanure A, Sabino E, The Brazilian Network for HIV-1 Isolation and Characterization 1996. A Nationwide effort to systematically monitor HIV-1 diversity in Brazil: Preliminary results. Mem Inst Oswaldo Cruz 91: 335-338.
17. Haastrecht HJA van, Bindels PJ, Sluijs TA 1996. The impact of drug users on inpatient hospital care during HIV epidemic in Amsterdam, Int J Epidemiol 4: 846-853.
18. Hendry RM, Hanson CV, Bongertz V, Morgado MG, Duarte A, Casseb J, Brigido L, Sabino E, Diaz R, Galvão-Castro B 1996. Immunoreactivity of Brazilian HIV isolates with different V3 motifs. Mem Inst Oswaldo Cruz 91: 347-348.
19. Kostrikis LG, Michalopoulou ZH, Cao Y, Moore JP, Ho DD 1996. Determining neutralization serotypes of HIV-1 by neural networks. AIDS Res Human Retrov 12: 1667-1669.
20. Lathey JL, Pratt RD, Spector SA 1997. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with HIV-I. J Inf Dis 175: 231-233.
21. Louisirirotchanakul S, Bobkov A, Shaffer N, Mastro TD, Wasi C, Weber J, Cheingsong-Popov R 1997. Sequence analysis of an HIV type 1 env subtype E isolate from Thailand with discordant V3-loop serotyping. AIDS Res Human Retrov 13: 807-808.
22. Manoff SB, Vlahov D, Herskowitz A 1996. HIV infection and infective endocarditis among injecting drug users. Epidemiology 7: 566-570.
23. Montefiori DC, Zhou J, Barnes B, Lake D, Hersch EM, Masuho Y, Lefkowitz JR JB 1991. Homotypic antibody response to fresh clinical isolates of human immunodeficiency virus. Virology 182: 635-43.
24. Moore J, Trkola A 1997. HIV Type 1 coreceptors, neutralization serotypes, and vaccine development. AIDS Res Human Retrov 13: 733-736.
25. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD 1996. Inter- and intra-clade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp 120 antigenic serotypes. J Virol 70: 427-44.
26. Morgado MG, Sabino E, Shpear E, Bongertz V, Brigido L, Guimarães MDC, Castilho EA, Galvão-Castro B, Mullins JI, Hendry RM, Mayer A 1994. V3 region polymorphism in HIV-1 from Brazil : Prevalence of subtype B strains divergent from the North American/European prototype and detection of subtype F. AIDS Res Human Retrov 10: 569-575.
27. Morgado MG, Guimarães ML, Gripp CBG, Costa CI, Santos VGV, Linhares-de-Carvalho MI, Bastos FI, Galvão-Castro B, Bongertz V 1996. HIV-1 diversity in patients from Rio de Janeiro, Brazil. TuA 103 XI Intl Conf AIDS, Vancouver, Canada.
28. Mikyas Y, Aziz N, Harawa N, Gorre M, Neagos N, Nogueira M, Wafer D, Dillon M, Boyer PJ, Bryson YJ, Plaeger S 1997. Immunologic activation during pregnancy: serial measurement of lymphocyte phenotype and serum activation markers in HIV-infected and uninfected women, J Reprod Immunol 33: 157-170.
29. Nyambi PN, Willems B, Janssens W, Fransen K, Nkengasong J, Peeters M, Vereecken K, Heyndrickx, Piot P, Van der Groen 1997. The neutralization relationship of HIV-1. HIV type 2, and SIVcpz is reflected in the genetic diversity that distinguishes them. AIDS Res Human Retro 13: 7-17.
30. Nyambi PN, Nkengason GJ, Lewi P, Andries K, Janssens W, Fransen K, Heyndricks L, Piot P, Van der Groen G 1996. Multivariate analysis of human immunodeficiency virus Type 1 neutralization data. J Virol 70: 6235-43.
31. Pau CP, Kai M, Holloman-Candal DL, Luo CC, Kalish ML, Schochetman G, Byers B, George JR, WHO Network for HIV isolation and characterization 1994. Antigenic variation and serotyping of HIV type 1 from four World Health Organization-sponsored vaccine sites. AIDS Res Hum Retrov 10: 1369-1377.
32. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Bolognesi DT, Fauci AS, Montefiori DC 1997. Neutralizing antibody responses to human immunodeficiency virus Type 1 in primary infection and long-term-nonprogressive infection. J Inf Dis 176: 924-932.
33. Potts K, Kalish M, Lott T, Orloff G, Luo CC, Bernard MA, Alves C, Badaró R, Suleiman J, Ferreira O, Schochetman G, Johnson W, Ou CY, Ho J 1993. Genetic heterogeneity of the V3 regio of the HIV-1 envelope glycoprotein in Brazil. AIDS 7: 1191-1197.
34. Simon F, Loussert-Ajaka I, Damond F, Saragosti S, Barin F, Brun-Vezinet F 1996. HIV type 1 diversity in northern Paris, France. AIDS Res Human Retrov 12: 1427-1433.
35. Stoneburner RL, Des Jarlais DC, Benezza D 1988. A larger spectrum of severe HIV-1 related disease in intravenous drug users in New York city. Science 242: 916-918.
36. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas III CF, Burton DR, Ho DD, Moore JP 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 69: 6609-6617.
37. Wasi L, Herring B, Ratham S, Vanichseni S, Mastro TD, Young NL, Rübsamen-Waigsam H, von Briesen H, Kalish ML, Luo CC 1995. Determination of HIV-1 in intravenous drug injectors in Bangkok, Thailand, using peptide binding immunoassay and HMA: evidence of increasing infection with subtype E. AIDS 9: 843-849.
38. Weber J, Fenyö EM, Beddows S, Kaleebu P, Björndal A, WHO Network for HIV Isolation and Characterization 1996. Neutralization serotypes of HIV-1 field isolates are not predicted by genetic subtyping. J Virol 70: 7827-7832.